Correlation Between Novartis and Cyclacel Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both Novartis and Cyclacel Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Novartis and Cyclacel Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Novartis AG ADR and Cyclacel Pharmaceuticals, you can compare the effects of market volatilities on Novartis and Cyclacel Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Novartis with a short position of Cyclacel Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Novartis and Cyclacel Pharmaceuticals.
Diversification Opportunities for Novartis and Cyclacel Pharmaceuticals
0.78 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Novartis and Cyclacel is 0.78. Overlapping area represents the amount of risk that can be diversified away by holding Novartis AG ADR and Cyclacel Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cyclacel Pharmaceuticals and Novartis is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Novartis AG ADR are associated (or correlated) with Cyclacel Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cyclacel Pharmaceuticals has no effect on the direction of Novartis i.e., Novartis and Cyclacel Pharmaceuticals go up and down completely randomly.
Pair Corralation between Novartis and Cyclacel Pharmaceuticals
Considering the 90-day investment horizon Novartis AG ADR is expected to generate 0.19 times more return on investment than Cyclacel Pharmaceuticals. However, Novartis AG ADR is 5.27 times less risky than Cyclacel Pharmaceuticals. It trades about 0.29 of its potential returns per unit of risk. Cyclacel Pharmaceuticals is currently generating about -0.05 per unit of risk. If you would invest 9,714 in Novartis AG ADR on November 3, 2024 and sell it today you would earn a total of 758.00 from holding Novartis AG ADR or generate 7.8% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Significant |
| Accuracy | 95.24% |
| Values | Daily Returns |
Novartis AG ADR vs. Cyclacel Pharmaceuticals
Performance |
| Timeline |
| Novartis AG ADR |
| Cyclacel Pharmaceuticals |
Novartis and Cyclacel Pharmaceuticals Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Novartis and Cyclacel Pharmaceuticals
The main advantage of trading using opposite Novartis and Cyclacel Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Novartis position performs unexpectedly, Cyclacel Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclacel Pharmaceuticals will offset losses from the drop in Cyclacel Pharmaceuticals' long position.| Novartis vs. AstraZeneca PLC ADR | Novartis vs. GlaxoSmithKline PLC ADR | Novartis vs. Roche Holding Ltd | Novartis vs. Bristol Myers Squibb |
| Cyclacel Pharmaceuticals vs. Ikena Oncology | Cyclacel Pharmaceuticals vs. Ovid Therapeutics | Cyclacel Pharmaceuticals vs. Connect Biopharma Holdings | Cyclacel Pharmaceuticals vs. Edgewise Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Other Complementary Tools
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |